These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 9568770)
21. Maximum flow rate--the single uroflowmetric parameter in clinical trials for benign prostatic hyperplasia? Homma Y; Imajo C; Kawabe K Int J Urol; 1995 Nov; 2(5):322-5. PubMed ID: 8749951 [TBL] [Abstract][Full Text] [Related]
22. Obstructive lower urinary tract symptoms correlate with erectile dysfunction. Elliott SP; Gulati M; Pasta DJ; Spitalny GM; Kane CJ; Yee R; Lue TF Urology; 2004 Jun; 63(6):1148-52. PubMed ID: 15183969 [TBL] [Abstract][Full Text] [Related]
23. [Evaluation of sexual function in men with symptomatic benign prostatic hyperplasia]. Shao Q; Song J; Guo YW; Lu WC; Du LD Zhonghua Nan Ke Xue; 2005 Jul; 11(7):505-7. PubMed ID: 16078666 [TBL] [Abstract][Full Text] [Related]
24. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes. Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250 [TBL] [Abstract][Full Text] [Related]
25. Lower urinary tract symptoms in young men: videourodynamic findings and correlation with noninvasive measures. Nitti VW; Lefkowitz G; Ficazzola M; Dixon CM J Urol; 2002 Jul; 168(1):135-8. PubMed ID: 12050507 [TBL] [Abstract][Full Text] [Related]
26. Association among the symptoms, quality of life and urodynamic parameters in patients with improved lower urinary tract symptoms following a transurethral resection of the prostate. Seki N; Yunoki T; Tomoda T; Takei M; Yamaguchi A; Naito S Neurourol Urodyn; 2008; 27(3):222-5. PubMed ID: 17580358 [TBL] [Abstract][Full Text] [Related]
27. Short term outcomes of high power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate. Volkan T; Ihsan TA; Yilmaz O; Emin O; Selcuk S; Koray K; Bedi O Eur Urol; 2005 Oct; 48(4):608-13. PubMed ID: 16135396 [TBL] [Abstract][Full Text] [Related]
28. Prediction of bladder outlet obstruction in men with lower urinary tract symptoms using artificial neural networks. Sonke GS; Heskes T; Verbeek AL; de la Rosette JJ; Kiemeney LA J Urol; 2000 Jan; 163(1):300-5. PubMed ID: 10604380 [TBL] [Abstract][Full Text] [Related]
29. Correlation between international prostate symptom score and uroflowmetry in patients with benign prostatic hyperplasia. Oranusi CK; Nwofor AE; Mbonu O Niger J Clin Pract; 2017 Apr; 20(4):454-458. PubMed ID: 28406126 [TBL] [Abstract][Full Text] [Related]
30. Do reported micturition symptoms on the American Urological Association Questionnaire correlate with 24-hour home uroflowmetry recordings? Matzkin H; Greenstein A; Prager-Geller T; Sofer M; Braf Z J Urol; 1996 Jan; 155(1):197-9. PubMed ID: 7490832 [TBL] [Abstract][Full Text] [Related]
31. Relationship between lower urinary tract symptoms and objective measures of benign prostatic hyperplasia: a Chinese survey. Wang JY; Liu M; Zhang YG; Zeng P; Ding Q; Huang J; He DL; Song B; Kong CZ; Pang J Chin Med J (Engl); 2008 Oct; 121(20):2042-5. PubMed ID: 19080272 [TBL] [Abstract][Full Text] [Related]
32. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. Nickel JC; Elhilali M; Vallancien G; BJU Int; 2005 Mar; 95(4):571-4. PubMed ID: 15705082 [TBL] [Abstract][Full Text] [Related]
33. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766 [TBL] [Abstract][Full Text] [Related]
34. Association between lower urinary tract symptoms and erectile dysfunction. Aslan G; Cavus E; Karas H; Oner O; Duran F; Esen A Arch Androl; 2006; 52(3):155-62. PubMed ID: 16574595 [TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. de Reijke TM; Klarskov P BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986 [TBL] [Abstract][Full Text] [Related]
36. [Uroflowmetry in the assessment of patients with benign prostatic hyperplasia]. Larosa M; Ferretti S; Salsi P; Simonazzi M Acta Biomed Ateneo Parmense; 1993; 64(1-2):17-22. PubMed ID: 7518630 [TBL] [Abstract][Full Text] [Related]
37. Urodynamic evaluation of patients with lower urinary tract symptoms and small prostate volume. Gomes CM; Nunes RV; Araújo RM; Sacomani CR; Trigo-Rocha FE; Bruschini H; Srougi M Urol Int; 2008; 81(2):129-34. PubMed ID: 18758208 [TBL] [Abstract][Full Text] [Related]
38. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631 [TBL] [Abstract][Full Text] [Related]
39. [Long-term results of lower urinary tract symptoms and urinary flow rate after transurethral resection of the prostate]. Tanaka Y; Masumori N; Tsukamoto T; Furuya S; Furuya R; Ogura H Hinyokika Kiyo; 2007 Jun; 53(6):369-73. PubMed ID: 17628933 [TBL] [Abstract][Full Text] [Related]